Salix Pharmaceuticals Recent News
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
5 Drug Companies Profiting From Generics
Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter
UPDATE: Piper Jaffray Raises PT on Salix Pharmaceuticals from $47 to $50
UPDATE: Duncan-Williams Color on Salix Pharmaceuticals Upgrade
Duncan Williams Upgrades Salix Pharmaceuticals To Buy, $47 PT
Piper Jaffray Reiterates Overweight Rating On Salix Pharmaceuticals
Duncan-Williams Maintains Buy Rating On Salix
UPDATE: Piper Jaffray Color On SLXP Target Increase
Piper Jaffray Raises PT on Salix Pharmceuticals To $42
Piper Jaffray Reports Salix Pharmaceuticals Not Alarmed By NEJM Letters
Jefferies Maintains Buy on Salix Pharmaceuticals (SLXP)
Piper Jaffray Lowers PT On Salix Pharmaceuticals To $39
Goldman Sachs Maintains Buy on Salix Pharmaceuticals (SLXP)
Piper Jaffray Reiterates Overweight on Salix Pharmaceuticals (SLXP)
Piper Jaffray Reiterates OW Rating, $60 PT On SLXP
Salix Pharmaceuticals, Inc. and the Colon Cancer Alliance Announce Colonoscopy For Dummies® is Now Available for Free Download
Goldman Sachs Initiates Coverage on Salix Pharmaceuticals (SLXP)
Favorable Update From Salix Pharmaceuticals
Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating
Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating
Salix Pharmaceuticals (SLXP) Shares Up Nearly 20%